Drug intelligence / Profile preview

NN-4101

Development stage: Preclinical
Lead developer: Novelty Nobility
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

NN-4101 is a bispecific antibody drug candidate developed by Novelty Nobility. It targets both vascular endothelial growth factor (VEGF) and c-Kit (stem cell growth factor receptor), acting as a modulator of these pathways. The primary therapeutic area for NN-4101 is eye diseases, with an active indication in retinal diseases. As of the latest update, its highest development phase is preclinical[1][3].

Targets

VEGFA (Vascular endothelial growth factor A)KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on NN-4101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NN-4101.

Explore the full profile